Cargando…

Prospects for personalizing antiviral therapy for hepatitis C virus with pharmacogenetics

Chronic hepatitis C virus (HCV) infection is a major cause of liver disease worldwide. HCV infection is currently treated with IFNα plus ribavirin for 24 to 48 weeks. This demanding therapy fails in up to 50% of patients, so the use of pharmacogenetic biomarkers to predict the outcome of treatment w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tavis, John E, Donlin, Maureen J, Aurora, Rajeev, Fan, Xiaofeng, Di Bisceglie, Adrian M
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3092093/ https://www.ncbi.nlm.nih.gov/pubmed/21345258 http://dx.doi.org/10.1186/gm222

Ejemplares similares

Hepatitis C Virus Diversity and Evolution in the Full Open-Reading Frame during Antiviral Therapy
por: Cannon, Nathan A., et al.
Publicado: (2008)

Contribution of Genome-Wide HCV Genetic Differences to Outcome of Interferon-Based Therapy in Caucasian American and African American Patients
por: Donlin, Maureen J., et al.
Publicado: (2010)

Genome-wide capture sequencing to detect hepatitis C virus at the end of antiviral therapy
por: Peng, Peng, et al.
Publicado: (2020)

Efficient amplification and cloning of near full-length hepatitis C virus genome from clinical samples
por: Fan, Xiaofeng, et al.
Publicado: (2006)

HCV Genome-Wide Genetic Analyses in Context of Disease Progression and Hepatocellular Carcinoma
por: Donlin, Maureen J., et al.
Publicado: (2014)

Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents
por: Kamal, Sanaa M
Publicado: (2014)

High-Resolution Quantification of Hepatitis C Virus Genome-Wide Mutation Load and Its Correlation with the Outcome of Peginterferon-Alpha2a and Ribavirin Combination Therapy
por: Wang, Weihua, et al.
Publicado: (2014)

Inhibition of C3 Convertase Activity by Hepatitis C Virus as an Additional Lesion in the Regulation of Complement Components
por: Kim, Hangeun, et al.
Publicado: (2014)

A Functional Interplay between Human Immunodeficiency Virus Type 1 Protease Residues 77 and 93 Involved in Differential Regulation of Precursor Autoprocessing and Mature Protease Activity
por: Counts, Christopher J., et al.
Publicado: (2015)

Global Transcriptome Profile of Cryptococcus neoformans during Exposure to Hydrogen Peroxide Induced Oxidative Stress
por: Upadhya, Rajendra, et al.
Publicado: (2013)

The Role of Pharmacogenetics in Personalizing the Antidepressant and Anxiolytic Therapy
por: Radosavljevic, Milica, et al.
Publicado: (2023)

2225. Acute Hepatitis C Virus Infections in HIV-Infected Persons in the Era of Direct-Acting Antiviral Therapy
por: Cartwright, Emily J, et al.
Publicado: (2018)

Antiviral Therapy for Hepatitis C Virus: Beyond the Standard of Care
por: Delang, Leen, et al.
Publicado: (2010)

Antiviral drugs against hepatitis C virus
por: Rehman, Sidra, et al.
Publicado: (2011)

Hepatitis C Virus and Antiviral Drug Resistance
por: Kim, Seungtaek, et al.
Publicado: (2016)

Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections
por: Rehermann, Barbara, et al.
Publicado: (2015)

Host pharmacogenetic factors that may affect liver neoplasm incidence upon using direct-acting antivirals for treating hepatitis C infection
por: Zidan, Ahmad M., et al.
Publicado: (2021)

Pharmacogenetics and pharmacogenomics in glaucoma therapeutics: the way to personalized therapy
por: Liao, Shiyu, et al.
Publicado: (2023)

Glycyrrhizin as antiviral agent against Hepatitis C Virus
por: Ashfaq, Usman A, et al.
Publicado: (2011)

Identification of 4-isopropyl–thiotropolone as a novel anti-microbial: regioselective synthesis, NMR characterization, and biological evaluation
por: Elagawany, Mohamed, et al.
Publicado: (2018)

The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics
por: Amin, Arwa M., et al.
Publicado: (2017)

Pharmacogenetic Testing: A Tool for Personalized Drug Therapy Optimization
por: Malsagova, Kristina A., et al.
Publicado: (2020)

Pharmacogenetics and personalized treatment of type 2 diabetes
por: Semiz, Sabina, et al.
Publicado: (2013)

Occult Hepatitis B Virus Infection in Patients With Chronic Hepatitis C Treated With Antiviral Therapy
por: Caviglia, Gian Paolo, et al.
Publicado: (2012)

Case report: Unusual viral evolutions following antiviral therapies in a patient with concurrent hepatitis B virus and hepatitis C virus infection
por: Su, Yi-Tse, et al.
Publicado: (2023)

The Hepatitis B Virus Ribonuclease H Is Sensitive to Inhibitors of the Human Immunodeficiency Virus Ribonuclease H and Integrase Enzymes
por: Tavis, John E., et al.
Publicado: (2013)

Neopterin as a Marker of Response to Antiviral Therapy in Hepatitis C Virus Patients
por: Oxenkrug, Gregory F., et al.
Publicado: (2012)

Study of the effect of antiviral therapy on homocysteinemia in hepatitis C virus- infected patients
por: Mustafa, Mubin, et al.
Publicado: (2012)

Antiviral Activity of Glycyrrhizin against Hepatitis C Virus In Vitro
por: Matsumoto, Yoshihiro, et al.
Publicado: (2013)

Plant-derived antivirals against hepatitis c virus infection
por: Jardim, Ana Carolina Gomes, et al.
Publicado: (2018)

Comparison of amplification enzymes for Hepatitis C Virus quasispecies analysis
por: Polyak, Stephen J, et al.
Publicado: (2005)

The role of direct oral anticoagulants in the era of COVID-19: are antiviral therapy and pharmacogenetics limiting factors?
por: Roguljić, Hrvoje, et al.
Publicado: (2022)

Altered Functionality of Anti-Bacterial Antibodies in Patients with Chronic Hepatitis C Virus Infection
por: Lamontagne, Anne, et al.
Publicado: (2013)

Rationally derived inhibitors of hepatitis C virus (HCV) p7 channel activity reveal prospect for bimodal antiviral therapy
por: Shaw, Joseph, et al.
Publicado: (2020)

Development of Autoimmune Hepatitis during Direct-acting Antiviral Therapy for Chronic Hepatitis C Virus Infection
por: Matsumoto, Kotaro, et al.
Publicado: (2018)

Clinical Application of CYP2C19 Pharmacogenetics Toward More Personalized Medicine
por: Lee, Su-Jun
Publicado: (2013)

Reply to Itoh et al., “Potential Use of Iron-Limiting Therapy against Cryptococcus neoformans and Effects of Caspofungin on the Host Immune System”
por: Donlin, Maureen J.
Publicado: (2022)

Asthma pharmacogenetics and the development of genetic profiles for personalized medicine
por: Ortega, Victor E, et al.
Publicado: (2015)

In Vitro Antiviral Activity of Tyrosinase from Mushroom Agaricus bisporus against Hepatitis C Virus
por: Lopez-Tejedor, David, et al.
Publicado: (2021)

Antiviral activity of zinc against hepatitis viruses: current status and future prospects
por: Kumar, Shiv, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_la4d68k3apiadp4pto1cf2fk70